AGENUS INC

Average Profitability
<0.0001%
Insider Buys Quantity
14
Insider Buys Sum
$17.5M
Insider Sells Quantity
0
Insider Sells Sum
$0

Insider Activity of AGENUS INC

According to the SEC Form 4 filings, AGENUS INC, being in a position of

  1. 10 percent owner at MiNK Therapeutics, Inc.,
    оver the last 12 months, has bought 22975 shares for $25,270, and sold 0 shares,
    over all time since 2021-10-19, has bought 1946694 shares for $17.5M, and sold 0 shares.

The largest purchase of all time was on 2021-10-19 and amounted to 1400000 shares of MiNK Therapeutics, Inc. for $16.8M.

Biography of AGENUS INC

No biography is available at this moment.

2023-10-16PurchaseMiNK Therapeutics, Inc.
INKT
10 percent owner
429
0.0012%
$1.10$472-15.1%
2023-10-13PurchaseMiNK Therapeutics, Inc.
INKT
10 percent owner
19,373
0.0561%
$1.10$21,310-14.84%
2023-10-12PurchaseMiNK Therapeutics, Inc.
INKT
10 percent owner
3,173
0.0089%
$1.10$3,488-17.77%
2023-10-04PurchaseMiNK Therapeutics, Inc.
INKT
10 percent owner
15,001
0.0465%
$1.09$16,380-17.59%
2023-08-29PurchaseMiNK Therapeutics, Inc.
INKT
10 percent owner
29,678
0.0826%
$1.52$45,016-38.68%
2023-08-28PurchaseMiNK Therapeutics, Inc.
INKT
10 percent owner
12,808
0.0371%
$1.45$18,570-33%
2023-08-24PurchaseMiNK Therapeutics, Inc.
INKT
10 percent owner
170,244
0.4482%
$1.54$262,908-37.33%
2023-05-11PurchaseMiNK Therapeutics, Inc.
INKT
10 percent owner
23,361
0.0606%
$1.43$33,348-34.57%
2023-05-10PurchaseMiNK Therapeutics, Inc.
INKT
10 percent owner
22,065
0.0649%
$1.51$33,296-29.8%
2023-05-05PurchaseMiNK Therapeutics, Inc.
INKT
10 percent owner
200
0.0005%
$1.25$250-31.96%
2023-05-05PurchaseMiNK Therapeutics, Inc.
INKT
10 percent owner
100,200
0.1772%
$0.95$95,100-31.96%
2023-05-04PurchaseMiNK Therapeutics, Inc.
INKT
10 percent owner
21,473
0.0618%
$1.22$26,246-13.8%
2023-05-03PurchaseMiNK Therapeutics, Inc.
INKT
10 percent owner
128,689
0.3494%
$1.08$138,843-7.69%
2021-10-19PurchaseMiNK Therapeutics, Inc.
INKT
10 percent owner
1.4M
4.2248%
$12.00$16.8M-79.46%
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.